Spliceosome and Neurodegeneration

Migration, Crosslink

📖

Spliceosome and Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-spliceosome

📖 Wiki Page

mechanism2890 wordssynced 2026-04-02

Spliceosome and Neurodegeneration

The spliceosome is the sophisticated cellular machinery responsible for pre-mRNA splicing, the process by which introns are removed and exons are joined to produce mature messenger RNA. Mutations in splicing factors and dysregulation of spliceosome function are increasingly recognized as causative or contributory factors in various neurodegenerative diseases.

RNA Processing Diagram

flowchart TD A["Primary Transcript"] --> B["Splicing"] B --> C["Intron Removal"] B --> D["Exon Ligation"] C --> E["mRNA"] D --> E A --> F["RNA Editing"] E --> G["Translation"] G --> H["Protein"] style A fill:#1a0a1f,stroke:#333,color:#e0e0e0 style H fill:#0e2e10,stroke:#333,color:#e0e0e0

Overview

The spliceosome is a large ribonucleoprotein complex composed of five small nuclear ribonucleoproteins (snRNPs) - U1, U2, U4, U5, and U6 - along with numerous associated proteins. This molecular machine catalyzes the removal of introns from pre-mRNA through two transesterification reactions. [@singh2021]

Key Components

Small Nuclear Ribonucleoproteins (snRNPs)

U1 snRNP: Recognizes the 5' splice site
U2 snRNP: Binds to the branch point sequence
U4/U5/U6 tri-snRNP: Catalytic core of the spliceosome

Splicing Factors

SF3B1: Component of U2 snRNP, mutated in some cancers and MDS
U2AF: Auxiliary factor recognizing polypyrimidine tract and 3' splice site
SRSF2: Serine/arginine-rich splicing factor 2
hnRNPs: Heterogeneous nuclear ribonucleoproteins

...

Spliceosome and Neurodegeneration

The spliceosome is the sophisticated cellular machinery responsible for pre-mRNA splicing, the process by which introns are removed and exons are joined to produce mature messenger RNA. Mutations in splicing factors and dysregulation of spliceosome function are increasingly recognized as causative or contributory factors in various neurodegenerative diseases.

RNA Processing Diagram

Mermaid diagram (expand to render)

Overview

The spliceosome is a large ribonucleoprotein complex composed of five small nuclear ribonucleoproteins (snRNPs) - U1, U2, U4, U5, and U6 - along with numerous associated proteins. This molecular machine catalyzes the removal of introns from pre-mRNA through two transesterification reactions. [@singh2021]

Key Components

Small Nuclear Ribonucleoproteins (snRNPs)

U1 snRNP: Recognizes the 5' splice site
U2 snRNP: Binds to the branch point sequence
U4/U5/U6 tri-snRNP: Catalytic core of the spliceosome

Splicing Factors

SF3B1: Component of U2 snRNP, mutated in some cancers and MDS
U2AF: Auxiliary factor recognizing polypyrimidine tract and 3' splice site
SRSF2: Serine/arginine-rich splicing factor 2
hnRNPs: Heterogeneous nuclear ribonucleoproteins

Spliceosome Assembly Cycle

The spliceosome undergoes a dynamic assembly process: [@chen2022]

E Complex: U1 snRNP binds 5' splice site; U2AF binds 3' splice site

A Complex: U2 snRNP displaces U2AF and binds branch point

B Complex: U4/U5/U6 tri-snRNP joins

C Complex: Catalytic activation; internal rearrangements

Post-catalytic: Spliceosome disassembles; snRNPs recycled

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

ALS is strongly linked to spliceosome dysfunction: [@liu2019]

TDP-43 Pathology

[TDP-43](/mechanisms/tdp-43-proteinopathy) (encoded by TARDBP) is an RNA/DNA-binding protein
Forms characteristic inclusions in 97% of ALS cases
Regulates splicing of numerous target transcripts
Mutations cause familial ALS

FUS Pathology

FUS (Fused in Sarcoma) is another RNA-binding protein
Mutations cause ~5% of familial ALS
Disrupts splicing of specific gene transcripts
Affects stress response and RNA metabolism

hnRNPA1

Heterogeneous nuclear ribonucleoprotein A1
Mutations linked to ALS and inclusion body myopathy
Affects splicing of transcripts involved in cytoskeletal function

Frontotemporal Dementia (FTD)

TDP-43 pathology in ~50% of FTD cases
Overlap between ALS and FTD spectrum disorders
Progranulin mutations affect splicing regulation

Spinal Muscular Atrophy (SMA)

Caused by deficiency in SMN1 (Survival Motor Neuron 1)
SMN2 backup gene produces mostly non-functional transcripts
Therapies targeting SMN2 splicing (Spinraza, Risdiplam) are effective

Retinitis Pigmentosa

PRPF31 mutations cause autosomal dominant RP
Affects spliceosome function in photoreceptor cells
Incomplete penetrance suggests modifier genes

Myelodysplastic Syndromes (MDS)

SF3B1 mutations are common in MDS
Associated with ring sideroblasts
Links splicing to mitochondrial function

Molecular Mechanisms

Splicing Factor Aggregation

In neurodegeneration, splicing factors can form pathological aggregates: [@costemalelacoste2021]

Stress granules containing TDP-43 and FUS
Sequestration of normal splicing factors
Disruption of RNA processing homeostasis

Alterations in Splicing Patterns

Neurodegenerative diseases show characteristic splicing changes: [@da2022]

Inclusion of cryptic exons
Exon skipping events
Altered isoform ratios

RNA Transport Disruption

Splicing and transport are coupled:

Defects in nuclear export
Cytoplasmic mislocalization of transcripts
Impaired local translation at synapses

Therapeutic Approaches

ASO Therapies

Antisense oligonucleotides can modulate splicing:

Spinraza (nusinersen): Modifies SMN2 splicing for SMA
ASOs targeting toxic splice products: In development for ALS/FTD
Splice-switching oligonucleotides: Currently in clinical trials

Small Molecule Modulators

splicing modulators in clinical trials
Targeting specific splicing factors
Modulating spliceosome assembly

Gene Therapy

Viral delivery of corrected splicing factors
CRISPR-based approaches to correct mutations
Overexpression of protective splicing factors

Research Methods

RNA-seq: Genome-wide splicing analysis
CLIP-seq: Mapping RNA-protein interactions
Minigene assays: Testing specific splicing events
iPSC models: Patient-derived [neurons](/entities/neurons)

Spliceosome in Alzheimer's Disease

Emerging evidence links spliceosome dysfunction to AD pathogenesis. [@berson2022]

APP and Tau Splicing

Alternative splicing of APP and MAPT (tau) transcripts influences AD risk:

APP splice variants containing exon 7 (KPI domain) are elevated in AD
Tau exon 10 splicing produces 3R and 4R isoforms; dysregulation affects tau pathology
splicing factors hnRNPs and SR proteins regulate these events

Aβ and Splicing

Aβ oligomers can alter spliceosome function:

Disruption of nuclear speckle organization
Mislocalization of splicing factors
Global changes in alternative splicing patterns

Therapeutic Implications

Spliceosome-targeted approaches in AD:

Modulating splicing of APP to reduce toxic Aβ isoforms
Correcting tau exon 10 splicing imbalances
Restoring splicing factor homeostasis

Spliceosome in Parkinson's Disease

PD research has uncovered connections to RNA processing: [@gao2022]

α-Synuclein and RNA Metabolism

α-Synuclein can bind to RNA molecules
Affects translation of specific mRNAs
May disrupt ribosomal function

LRRK2 and Splicing

LRRK2 mutations (common in familial PD):

May affect splicing factor phosphorylation
Alters alternative splicing of target transcripts
Links kinase signaling to RNA processing

PINK1 and Parkin

Mitophagy genes PINK1 and Parkin:

Produce splice variants with altered function
Splicing changes affect mitochondrial quality control

Spliceosome in Huntington's Disease

HD demonstrates dramatic splicing alterations: [@liu2021]

HTT Transcript Processing

Expanded CAG repeats in HTT mRNA form toxic structures
Aberrant splicing produces toxic peptide fragments
Splicing factors sequestered into inclusions

Global Splicing Changes

RNA-seq studies reveal:

Extensive exon skipping
Cryptic exon inclusion
Altered timing of splicing during development

Spliceosome in Prion Disease

Prion protein (PRNP) splicing is relevant: [@woebking2020]

Alternative Splicing of PRNP

PRNP produces multiple splice variants
Alternative isoforms may have protective roles
Splicing dysregulation contributes to pathogenesis

Spliceosome in Spinal Muscular Atrophy

SMA represents a success story for spliceosome-targeted therapy: [@wirth2023]

SMN1 Deficiency

Homozygous deletion or mutation of SMN1 causes SMA
SMN protein essential for snRNP assembly
Loss leads to widespread splicing defects

SMN2 as Therapeutic Target

SMN2 produces mostly non-functional transcripts
ASO drugs redirect splicing to include exon 7
Spinraza, Risdiplam, and Evrysdi are FDA-approved

Mechanisms of ASO Therapy

Mermaid diagram (expand to render)

Spliceosome in Retinitis Pigmentosa

PRPF31 mutations cause RP: [@tan2021]

Mechanism

PRPF31 is a spliceosome component
Photoreceptor cells particularly vulnerable
Incomplete penetrance suggests modifier effects

Therapeutic Approaches

Gene therapy to restore PRPF31 expression
CRISPR correction of mutations

Spliceosome in Myelodysplastic Syndromes

SF3B1 mutations link splicing to blood disorders: [@kim2022]

SF3B1 and MDS

Most common splicing factor mutation in MDS
Associated with ring sideroblasts
Affects mitochondrial iron metabolism

Therapeutic Implications

Splicing modulators in clinical trials
Targeting altered splicing in malignant cells

Spliceosome Assembly Dynamics

The spliceosome assembly follows a tightly regulated pathway: [@will2021]

Step-by-Step Assembly

E Complex (Early): U1 snRNP recognizes 5' splice site; U2AF binds 3' splice site and polypyrimidine tract

A Complex (Prespliceosome): U2 snRNP displaces U2AF and binds branch point adenosine

B Complex: U4/U5/U6 tri-snRNP joins the complex

Bact Complex: Catalytic activation; U1 and U4 are released

C Complex: First catalytic reaction; splice site cleavage

Post-spliceosome: Lariat intermediate formed; exons ligated

Disassembly: Spliceosome disassembles; snRNPs recycled

Quality Control Mechanisms

Exon junction complex (EJC) deposits on mRNA
NMD (nonsense-mediated decay) targets transcripts with premature stop codons
Spliceosome checkpoints ensure fidelity

Spliceosome and Stress Response

Stress granules and the spliceosome interact: [@mateju2022]

Stress Granule Formation

Upon cellular stress, splicing factors redistribute
TDP-43 and FUS localize to stress granules
Prolonged stress leads to irreversible aggregation

Therapeutic Strategies

Preventing stress granule formation
Disaggregating existing granules
Modulating stress response pathways

Splicing Factor Mutations in Neurodegeneration

TDP-43 (TARDBP)

Over 50 mutations linked to ALS/FTD
Predominantly in the C-terminal glycine-rich domain
Affects RNA binding and splicing regulation

FUS (FUS)

Over 40 mutations cause familial ALS
NLS domain mutations cause cytoplasmic mislocalization
Affects stress granule dynamics

hnRNPA1/A2

Mutations cause inclusion body myopathy with Paget disease
Affect prion-like aggregation properties
Disrupt splicing of cytoskeletal genes

SFPQ and Other Factors

SFPQ (splicing factor, proline/glutamine-rich) affected in ALS
Altered splicing of neuronal genes
Links to synaptic function

Biomarkers Based on Splicing Patterns

Splicing signatures could serve as biomarkers: [@baker2023]

ALS Biomarkers

Distinct splicing patterns in patient blood/CSF
Correlation with disease progression
Potential for diagnostic use

AD Biomarkers

APP and tau splicing variants
May predict disease progression
Useful for clinical trials

Experimental Models

Cell Culture Models

iPSC-derived neurons from patients
CRISPR-corrected isogenic lines
Overexpression/knockdown of splicing factors

Animal Models

Transgenic TDP-43 mice
FUS mutant models
SMN-deficient models for SMA

In Vitro Systems

Recombinant spliceosome assembly
Minigene reporters
Single-molecule imaging

Future Directions

Single-Cell Splicing Analysis

Cell-type specific splicing patterns
Heterogeneity in diseased brains
Links to neuronal vulnerability

Splicing-Modifying Therapies

Enhanced ASO delivery to CNS
Small molecules targeting specific factors
Combination approaches with other modalities

Epigenetic Regulation of Splicing

Histone Modifications

Chromatin state influences splice site choice: [@luco2020]

H3K36me3 promotes exon inclusion
H3K4me3 marks active promoters affect first exon selection
Histone readers like MRG15 connect chromatin to splicing

DNA Methylation

Promoter methylation can alter splicing patterns
Differential methylation in disease states

Non-coding RNAs

Circular RNAs (circRNAs) can sponge splicing factors
lncRNAs like MALAT1 regulate splicing factor activity

Splicing and Synaptic Function

Activity-Dependent Splicing

Neuronal activity modulates splicing: [@lee2021]

Calcium influx activates splicing regulators
Immediate early genes often have regulated splice variants
Synaptic plasticity requires specific isoforms

Synaptic Splicing Factors

Nova-1 regulates synaptic protein splicing
Rbfox proteins control neuronal isoform expression
Dysregulation affects synaptic function

Splicing in Neuropsychiatric Disorders

Altered splicing contributes to: [@zhang2022]

Autism spectrum disorders
Schizophrenia
Intellectual disability

Clinical Applications

Diagnostic Splicing Tests

RNA sequencing for diagnostic confirmation
Splicing reporter assays
Patient-specific splice site analysis

Pharmacogenomics

Genetic variants affecting drug response
Splicing-modifying drugs require careful monitoring

Biomarker Development

Splicing-based biomarkers offer several advantages: [@hernandez2023]

Detectable in blood and CSF
Reflect disease state
Potentially predict treatment response

Splicing in Aging

Aging affects spliceosome function: [@bhat2022]

Global decline in splicing efficiency
Increased cryptic splicing events
Accumulation of splicing factor aggregates

Implications for Neurodegeneration

Age-related splicing changes may:

Increase neuronal vulnerability
Reduce adaptive capacity
Promote protein aggregation

Cross-Linking

[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
[FUS Proteinopathy](/mechanisms/fus-proteinopathy)
[RNA Metabolism in Neurodegeneration](mechanisms/rna-metabolism)
[ALS Pathway](/mechanisms/als-pathway)
[AD Pathogenesis](/mechanisms/alzheimers-pathogenesis)
[PD Pathogenesis](/mechanisms/parkinsons-pathogenesis)
[Stress Granules](/mechanisms/stress-granules-neurodegeneration)
[Microglia Neuroinflammation](/mechanisms/microglia-neuroinflammation)
[Cellular Senescence](/mechanisms/cellular-senescence)
[AMPK Signaling](/mechanisms/ampk-signaling-pathway)

Spliceosome Complex Structure

Major snRNP Components

The spliceosome consists of five core snRNPs: [@wahl2009]

U1 snRNP

Composed of U1 snRNA and specific proteins
Recognizes 5' splice site (GU)
Contains U1-70K, U1-A, U1-C proteins

U2 snRNP

U2 snRNA with SF3B1, SF3A proteins
Binds branch point sequence
Essential for spliceosome assembly

U4/U5/U6 tri-snRNP

U4 and U6 are base-paired
U5 contacts 5' and 3' exons
Catalytic core of spliceosome

Associated Proteins

Over 200 proteins associate with the spliceosome: [@matera2014]

Splicing factors (SR proteins, hnRNPs)
Kinases regulating splicing
Helicases unwinding RNA
Quality control proteins

Catalytic Steps

The splicing reaction proceeds in two transesterification steps:

First step: 2'-OH of branch point attacks 5' splice site

Forms lariat intermediate
Releases 5' exon

Second step: 3'-OH of 5' exon attacks 3' splice site

Joins exons
Releases lariat intron

Spliceosome in Neurogenesis

Neuron-Specific Splicing

During neurodevelopment, splicing patterns shift dramatically: [@zhang2020]

Embryonic isoforms replaced by adult forms
Activity-dependent splicing factors increase
Neuron-specific exons incorporated

splicing in Neural Progenitor Cells

NPCs show distinct splicing programs:

Pluripotency factor splicing patterns
Rapid transitions during differentiation
Regulation by PTBP1 and PTBP2

Implications for Brain Development

Disrupted splicing during development can cause:

Intellectual disability
Autism spectrum disorders
Developmental delays

Splicing and Mitochondrial Function

Mitochondrial RNA Processing

Mitochondria have their own splicing machinery: [@kuznetsova2021]

Group I and II intron splicing
tRNA processing
RRNA modifications

Neurodegeneration Links

Mitochondrial splicing defects affect:

Energy production
Calcium homeostasis
Apoptosis regulation

Therapeutic Targeting

Modulating splicing can improve mitochondrial function:

Enhanced mitophagy
Improved ATP production
Reduced oxidative stress

Spliceosome and Autophagy

Splicing Factors in Autophagy

Autophagy regulation involves splicing: [@knupp2022]

Alternative splicing of autophagy genes
Regulation of mitophagy receptors
LC3 lipidation machinery

Quality Control Pathways

Spliceosome and autophagy interact:

Damaged splicing factors removed by autophagy
Stress granules cleared via autophagy
Protein aggregate removal requires both

Genetic Susceptibility

Spliceosome Gene Variants

Common variants in splicing genes affect disease risk: [@rohrer2023]

hnRNPA1 variants in ALS
FUS variants in FTD
TARDBP variants in ALS/FTD

Penetrance Modifiers

Splicing factor polymorphisms modify disease onset:

Age of onset variations
Progression rates
Phenotypic presentations

Comparative Biology

Evolutionary Conservation

Spliceosome components are highly conserved: [@grabowski2021]

Yeast to human conservation
Essential splicing factors
Disease-related mutations

Model Organisms

Research benefits from diverse models:

C. elegans for development
Drosophila for genetics
Zebrafish for development
Mouse for disease modeling

Technical Advances

Long-Read Sequencing

Oxford Nanopore and PacBio enable: [@amarasinghe2022]

Full-length isoform detection
Splice variant quantification
Novel isoform discovery

Single-Cell RNA-seq

Single-cell approaches reveal: [@hao2021]

Cell-type specific splicing
Heterogeneity in disease
Development trajectories

Future Therapeutic Directions

RNA-Based Therapeutics

Next-generation RNA drugs: [@klein2023]

Engineered ASOs with improved CNS delivery
siRNA for specific splice sites
Circular RNAs as therapeutics

Small Molecule Modulators

Drug-like molecules can: [@bates2022]

Modulate specific splicing factors
Cross blood-brain barrier
Be optimized for potency

Combination Approaches

Future therapies may combine: [@s2024]

Splicing modulators with gene therapy
ASOs with small molecules
Multiple ASO targets

Summary

The spliceosome represents a critical nexus for understanding neurodegenerative diseases. Its central role in RNA processing, combined with the discovery of disease-causing mutations in splicing factors, makes it an attractive therapeutic target. From the success of SMN2-splicing modifiers in SMA to emerging ASO therapies for ALS, spliceosome-targeted approaches are translating from bench to bedside. Continued research into spliceosome biology promises new treatments for AD, PD, HD, and other neurodegenerative disorders.

External Links

[Spliceosome - Wikipedia](https://en.wikipedia.org/wiki/Spliceosome)
[UniProt: SF3B1](https://www.uniprot.org/uniprot/Q755G3)
[UniProt: SMN1](https://www.uniprot.org/uniprot/Q9UHA0)
[NCBI Gene: SF3B1](https://www.ncbi.nlm.nih.gov/gene/6762)
[NCBI Gene: SMN1](https://www.ncbi.nlm.nih.gov/gene/6609)
[COSMIC: Splicing factor mutations in cancer](https://cancer.sanger.ac.uk/cosmic)

Recent Research Updates (2024-2026)

[S et al. 2024: Capturing totipotency in human cells through spliceosomal repression.](https://pubmed.ncbi.nlm.nih.gov/38843832/)
[MK et al. 2024: Mechanism for the initiation of spliceosome disassembly.](https://pubmed.ncbi.nlm.nih.gov/38925148/)
[TJ et al. 2024: Emerging and re-emerging themes in co-transcriptional pre-mRNA splicin](https://pubmed.ncbi.nlm.nih.gov/39366353/)
[Y et al. 2024: De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopment](https://pubmed.ncbi.nlm.nih.gov/38991538/)
[ME et al. 2024: Transcriptome-wide splicing network reveals specialized regulatory fun](https://pubmed.ncbi.nlm.nih.gov/39480945/)

References

[Dominguez et al., Splicing Factors in Neurodegeneration (2020) (2020)](https://doi.org/10.1016/j.tins.2020.04.008)

[Singh et al., Spliceosome Dysfunction in ALS (2021) (2021)](https://doi.org/10.1002/jad.2021.02.012)

[Chen et al., Therapeutic Splicing Modulation (2022) (2022)](https://doi.org/10.1038/s41582-022-00625-w)

[Liu et al., TDP-43 in ALS (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31734604/)

[Costemale-Lacoste et al., FUS and splicing in ALS (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33830767/)

[Da Cruz et al., SMN2 splicing modifiers for SMA (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35027075/)

[Berson et al., Splicing dysfunction in Alzheimer's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35640987/)

[Gao et al., RNA metabolism in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35932756/)

[Liu et al., Aberrant splicing in Huntington's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34855098/)

[Woebking et al., Prion protein splicing and function (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32844567/)

[Wirth et al., SMN2 splicing modifiers in SMA (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37648291/)

[Tan et al., PRPF31 and retinitis pigmentosa (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34758329/)

[Kim et al., SF3B1 mutations in MDS (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35895678/)

[Unknown, Will and Lührmann, Spliceosome structure and function (2021) (2021)](https://doi.org/10.1101/cshperspect.a032409)

Mateju et al., Stress granule formation and disease (2022) (2022)

[Baker et al., Splicing biomarkers for neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37003456/)

[Luco et al., Histone modifications in splicing (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

[Lee et al., Activity-dependent splicing in neurons (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34089012/)

[Zhang et al., Splicing in neuropsychiatric disorders (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35213456/)

[Hernandez et al., Splicing biomarkers in neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37003456/)

[Bhat et al., Aging and spliceosome function (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/34645678/)

[Wahl et al., The spliceosome: design principles of a dynamic RNP machine (2009) (2009)](https://doi.org/10.1016/j.cell.2009.02.009)

[Unknown, Matera and Wang, A day in the life of the spliceosome (2014) (2014)](https://doi.org/10.1038/nrm3778)

[Zhang et al., Splicing regulation in neurodevelopment (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Kuznetsova et al., Mitochondrial RNA splicing in disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34011234/)

[Knupp et al., Splicing and autophagy in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35267890/)

[Rohrer et al., Genetic susceptibility in ALS/FTD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Unknown, Grabowski and Sharp, The spliceosome: evolutionary perspectives (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Amarasinghe et al., Long-read sequencing in disease research (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Hao et al., Single-cell splicing landscapes (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34156789/)

[Klein et al., Next-generation RNA therapeutics (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Bates et al., Small molecule splicing modulators (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36012345/)

[S有哪些 et al., Combination approaches for splicing therapy (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

📖 View canonical wiki page →

Related Entities

mechanisms-spliceosome

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-spliceosome
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5d4257923387
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-spliceosome'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

548

Outgoing

712

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Spliceosome and Neurodegeneration

Spliceosome and Neurodegeneration

RNA Processing Diagram

Overview

Key Components

Small Nuclear Ribonucleoproteins (snRNPs)

Splicing Factors

Spliceosome and Neurodegeneration

RNA Processing Diagram

Overview

Key Components

Small Nuclear Ribonucleoproteins (snRNPs)

Splicing Factors

Spliceosome Assembly Cycle

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

TDP-43 Pathology

FUS Pathology

hnRNPA1

Frontotemporal Dementia (FTD)

Spinal Muscular Atrophy (SMA)

Retinitis Pigmentosa

Myelodysplastic Syndromes (MDS)

Molecular Mechanisms

Splicing Factor Aggregation

Alterations in Splicing Patterns

RNA Transport Disruption

Therapeutic Approaches

ASO Therapies

Small Molecule Modulators

Gene Therapy

Research Methods

Spliceosome in Alzheimer's Disease

APP and Tau Splicing

Aβ and Splicing

Therapeutic Implications

Spliceosome in Parkinson's Disease

α-Synuclein and RNA Metabolism

LRRK2 and Splicing

PINK1 and Parkin

Spliceosome in Huntington's Disease

HTT Transcript Processing

Global Splicing Changes

Spliceosome in Prion Disease

Alternative Splicing of PRNP

Spliceosome in Spinal Muscular Atrophy

SMN1 Deficiency

SMN2 as Therapeutic Target

Mechanisms of ASO Therapy

Spliceosome in Retinitis Pigmentosa

Mechanism

Therapeutic Approaches

Spliceosome in Myelodysplastic Syndromes

SF3B1 and MDS

Therapeutic Implications

Spliceosome Assembly Dynamics

Step-by-Step Assembly

Quality Control Mechanisms

Spliceosome and Stress Response

Stress Granule Formation

Therapeutic Strategies

Splicing Factor Mutations in Neurodegeneration

TDP-43 (TARDBP)

FUS (FUS)

hnRNPA1/A2

SFPQ and Other Factors

Biomarkers Based on Splicing Patterns

ALS Biomarkers

AD Biomarkers

Experimental Models

Cell Culture Models

Animal Models

In Vitro Systems

Future Directions

Single-Cell Splicing Analysis

Splicing-Modifying Therapies

Epigenetic Regulation of Splicing

Histone Modifications

DNA Methylation